Longitudinal Measurements of Inflammatory Mediators in Patients at Risk of Sepsis in the Emergency Department

1. **Berta Cistero** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. Department of Medicine, PhD Programme in Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. BCistero@tauli.cat
2. **Veronica Monforte** Critical Care Center, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Department of Medicine, Universitat Autònoma de Barcelona, Sabadell, Spain. Department of Medicine, PhD Programme in Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. vmonforte@tauli.cat
3. **Marta Camprubi-Rimblas** Critical Care Center, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Department of Medicine, Universitat Autònoma de Barcelona, Sabadell, Spain. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. mcamprubi@tauli.cat
4. **Aina Areny-Balaguero** Critical Care Center, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Department of Medicine, Universitat Autònoma de Barcelona, Sabadell, Spain. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. aareny@tauli.cat
5. **Elena Campana-Duel** Critical Care Center, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Department of Medicine, Universitat Autònoma de Barcelona, Sabadell, Spain. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. ecampanad@tauli.cat
6. **Aida Fernandez** Critical Care Center, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Department of Medicine, Universitat Autònoma de Barcelona, Sabadell, Spain. aidafernandezolivares99@gmail.com
7. **Antonio Casabella Pernas** Microbiology Section, Laboratory Medicine Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain acasabella@tauli.cat
8. **Elisa Nuez Zaragoza** Microbiology Section, Laboratory Medicine Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain enuez@tauli.cat
9. **Iu Martin** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. imartinr@tauli.cat
10. **Adriana Tomas** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. ALACASTA@tauli.cat
11. **Irune Minarro** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. iminarro@tauli.cat
12. **Marta Vila** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. mvila@tauli.cat
13. **Mireia Cuevas** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. mcuevasm@tauli.cat
14. **Mar Sanchez** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. MSANCHEZA@tauli.cat
15. **Xavier Belda** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. xbelda@tauli.cat

16. **Monica Lopez Rodriguez** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. MLopezR@tauli.cat

17. **Tiago Teles** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. ttelesdecastrog@tauli.cat

18. **Maria F. Savone** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. Msavone@tauli.cat

19. **Carlos Stable** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. cestable@tauli.cat

20. **Patricia Salom Merce** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. psalom@tauli.cat

21. **Carla Guijarro Viudez** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. cguijarro@tauli.cat

22. **Juan Tajan** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. jtajan@tauli.cat

23. **Gemma Goma Fernandez** Critical Care Center, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Department of Medicine, Universitat Autònoma de Barcelona, Sabadell, Spain. GGoma@tauli.cat

24. **Maria L. Martinez** Critical Care Center, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Department of Medicine, Universitat Autònoma de Barcelona, Sabadell, Spain.

25. **Lina Kramer** Intensive Care & Laboratory of Experimental Intensive Care and Anesthesiology (LEICA), Amsterdam UMC Location AMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands. l.kramer1@amsterdamumc.nl

26. **Rombout van Amstel** Intensive Care & Laboratory of Experimental Intensive Care and Anesthesiology (LEICA), Amsterdam UMC Location AMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands. r.b.vanamstel@amsterdamumc.nl

27. **Emilio Diaz Santos** Critical Care Center, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Department of Medicine, Universitat Autònoma de Barcelona, Sabadell, Spain. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. ediazsan@tauli.cat

28. **Lluis Blanch** Critical Care Center, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Department of Medicine, Universitat Autònoma de Barcelona, Sabadell, Spain. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. LBlanch@tauli.cat

29. **Emilio M. Gene Tous** Emergency Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. EGene@tauli.cat

30. **Lieuwe DJ. Bos** Intensive Care & Laboratory of Experimental Intensive Care and Anesthesiology (LEICA), Amsterdam UMC Location AMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands. l.d.bos@amsterdamumc.nl

31. **Antonio Artigas Raventos**[†*] Critical Care Center, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Department of Medicine, Universitat Autònoma de Barcelona, Sabadell, Spain. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. AArtigas@tauli.cat

32. **Adrian Ceccato**[†*] Critical Care Center, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Department of Medicine, Universitat Autònoma de Barcelona, Sabadell, Spain. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. aaceccato@tauli.cat

† These authors contributed equally.
*Corresponding authors

Corresponding autor
Adrian Ceccato
Institut d'Investigació i Innovació Parc Taulí I3PT
Plaça Torre de l'Aigua, s/n, 08208 Sabadell
aaceccato@tauli.cat; adrianceccato@gmail.com
Alternative Corresponding author
Prof. Antonio Artigas
Parc Taulí University Hospital
Parc Tauli 1, 08208 Sabadell Spain.
aartigas@tauli.cat

ABSTRACT

Sepsis is a complex condition with time‐dependent evolution, and longitudinal biomarker dynamics may improve its characterisation. We hypothesised that biomarker kinetics are associated with sepsis, the intensity of organ dysfunction, and patient survival.

This single‐centre, prospective, observational study included adult patients presenting to the Emergency Department with suspected infection and a National Early Warning Score 2 (NEWS2) ≥3. Blood samples were collected at baseline, 4 and 24 hours. Linear mixed models assessed associations between biomarker trajectories, sepsis diagnosis, and organ dysfunction severity. Joint models evaluated the predictive value of biomarker kinetics during the first 24 hours for in‐hospital mortality.

Of 214 screened patients, 173 were analysed and 137(79%) developed sepsis. Linear mixed models showed significant time‐dependent decreases in IL10(β −0.016, 95%CI −0.028 to −0.004), IL1RN(β −0.014, 95%CI −0.024 to −0.004), and IL6(β −0.012, 95%CI −0.024 to 0.00). Sepsis diagnosis was associated with higher IL1RN(β 0.378, 95%CI 0.153−0.603) and TNFRSF1A(β 0.40, 95%CI 0.21−0.58); a significant interaction between sepsis and time was observed only for IL6.

Increasing SOFA scores correlated with elevated IL10(β 0.048), IL1RN(β 0.044), CCL2(β 0.046), TNFRSF1A(β 0.050), and procalcitonin(PCT; β 2.63), all $p<0.01$. The SOFA−time interaction was significant only for IL6 (β −0.003, 95%CI −0.005 to −0.001). Joint survival models adjusted for age and maximum SOFA identified IL8 (HR 0.655, 95%CrI 0.582−0.728), TNFRSF1A (HR 0.505, 95%CrI 0.419−0.682), and PCT (HR 1.004, 95%CrI 1.001−1.008) as outcome predictors.

In conclusion, sepsis and organ dysfunction severity are associated with distinct inflammatory biomarker levels and kinetics. IL6 showed a unique time‐dependent relationship, while TNFRSF1A, IL8 and PCT dynamics were associated with survival.

Keywords: Sepsis; Inflammatory markers; Cytokines; Survival.

Sepsis is a heterogeneous condition that causes millions of deaths each year [1]. It is defined as a dysregulated inflammatory response to an infection that leads to organ dysfunction [2]. Sepsis has been described as a time-dependent disease, since it has been shown that early bundle measures improve prognosis [3]. However, the time zero is unclear, and there is a lack of diagnostic tools for early detection.

In recent decades, the significant increase in general knowledge about sepsis physiopathology has enabled several hypotheses to be developed aiming to improve prognosis. However, when tested in clinical studies, these treatments have failed to demonstrate clinical benefits [4]. Profiling immune and inflammatory patterns may be a promising approach to personalising medicine, reducing the risk of harm, and increasing the likelihood of success [5–8]. Experimental models and clinical observations have enabled us to understand how inflammatory mediators evolve in sepsis [9]. Critically ill patients with sepsis exhibit increases in cytokine levels, followed by a subsequent decrease [10]. However, these observations were limited to patients admitted to the intensive care unit (ICU).

A better understanding of longitudinal cytokine/biomarker dynamics could help us to characterise sepsis more effectively [11]. Sepsis is a rapidly evolving syndrome in which the host response and organ dysfunction change markedly over time. Whether early cytokine dynamics could be related to clinical events has not been adequately addressed in previous research. Dismissing the temporal dimension of biomarkers may lead to misclassification of patients' true risk and underestimate their potential for guiding individualised therapeutic decisions.

Pro-inflammatory cytokines, such as tumour necrosis factor (TNF), interleukin (IL)-1B and IL6, the anti-inflammatory cytokine IL10, chemokines IL-8 and C-C motif chemokine ligand 2 (CCL2), IL-1 receptor antagonist (IL1RN) and soluble TNF receptors (sTNFRs), as well as other inflammatory mediators or acute-phase reactants such as soluble triggering receptor expressed on myeloid cells-1 (STREM-1) and procalcitonin (PCT), have been

proposed as biomarkers for sepsis identification or prognosis for their physiopathology role in the development of the condition[9].

We hypothesised that biomarker levels are associated with sepsis and the severity of organ dysfunction, resulting in different dynamics over time. Biomarker kinetics may also be useful for predicting survival.

Our aims were to analyse (1) the kinetics of inflammatory mediators over time in patients coming to the emergency department by infection during the first 24 hours, (2) to understand whether sepsis might alter the trajectory of biomarkers, (3) whether the severity of sepsis, as measured by the SOFA score, were associated with biomarker values at different times, and (4) whether dynamic measures could aid survival prediction.

METHODS

Study Design

This was a single-center, prospective, observational study conducted at Hospital Parc Taulí de Sabadell, in collaboration with the Institut d'Investigació i Innovació Parc Taulí (I3PT).

Study Population

We included adult patients who presented to the Emergency Department (ED) with suspected infection.

Patients were included if they fulfilled the following criteria: age ≥18 years, suspected infection with a National Early Warning Score 2 (NEWS) score ≥3[12], and willingness to provide written informed consent. Patients were excluded if they were pregnant or breastfeeding, receiving immunosuppressive therapy, antineoplastic chemotherapy, or chronic corticosteroids (prednisone ≥10 mg/day for ≥3 weeks), had received an organ transplant, had been included in another study within the previous 60 days, had been hospitalized for >48 hours, had a life expectancy of less than 6 months, or had any limitation of therapeutic effort.

Study Procedures

Eligible patients were assessed by ED physicians. Upon obtaining informed consent, a 4 mL blood sample was collected at baseline (0h), 4h, and 24h. Vital signs (heart rate, respiratory rate, blood pressure, oxygen saturation, body temperature, and level of consciousness) were recorded at 0h, 4h, and 24h. Laboratory markers of inflammation and organ dysfunction, including differential white blood cell count, lactate, bilirubin, and creatinine, were measured at the same time points.

The final diagnosis of sepsis was determined according to Sepsis-3 criteria[2]: suspected infection and a ≥2 point increase in the Sequential Organ Failure Assessment (SOFA)[13] score, as confirmed independently by two blinded researchers (BC-AC). Clinical assessment included evaluation of organ dysfunction (e.g., oliguria, altered mental status, respiratory distress), as well as sepsis scoring systems (qSOFA, NEWS), and microbiological data (e.g., blood, sputum, urine, skin, and stool cultures). Patients with a confirmed non-infectious diagnosis after discharge were excluded from the study.

Blood samples were centrifuged, and plasma was separated and stored at −80°C. At the end of the study, samples were thawed and analysed for inflammatory mediators (IL1B, IL1RN, IL6, IL7, IL8, IL10, IL17A, TNF, TNF receptor superfamily member 1A (TNFRSF1A), interferon gamma (IFNG), CCL2 and CCL7) using a multiplexed bead-based immunoassay (Invitrogen PPX-12-MXRWGUZ), and PCT (FineTests ref. EH0341) and sTREM-1 (Invitrogen ref: EHTREM1) were analysed by ELISA methods. The study was purely observational and did not involve any interventions or modifications to standard clinical care. Patients were treated following local guidelines and the survival sepsis campaign recommendations [3,14,15].

The primary outcome was the development of sepsis, as defined above, and in-hospital mortality

This study is reported following STROBE guidelines [16]. The institution's Ethical Review Board approved the study (Comité de Ética de Investigación con medicamentos del Parc Taulí 2022/3004), which was performed following the ethical standards laid down in the

1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all patients or their legally authorised surrogates.

Statistical Analysis

Descriptives

Continuous variables were summarized using means, medians, standard deviations, and interquartile ranges. Categorical variables were described as frequencies and percentages. Comparisons between groups were performed using the chi-square or Fisher's exact test for categorical variables, and the Student's t-test or Mann-Whitney U test for continuous variables, as appropriate.

Time-to-event data were analyzed using Kaplan-Meier curves and compared using the log-rank or Gehan-Breslow-Wilcoxon tests.

Missing data and data transformations

Missing data was considered as missing not at random, and was not imputed. For those measures below or above the limit of quantification, we imputed the minimum or maximum value.

Due to the non-normal distribution of cytokine data, log10+1 transformation was applied before analysis.

Analyses of biomarker kinetics and associations to survival

Biomarker trajectories over time were analysed using linear mixed-effects models. The models included fixed effects for group (sepsis or non-sepsis), time (numeric, increasing with one unit each hour), and their interaction, and random effects as patient-specific intercepts and random slopes for time.

To assess the association between organ dysfunction severity and biomarker levels, linear mixed effects models were fit for biomarker levels (except for PCT and STREM-1), with time (numeric) and SOFA score as fixed effects, and patient-specific intercepts and time slope as random effects. We also tested for interaction between SOFA and time (p-value

<0.05). The NLME package [17] was used to fit the mixed-effects models. Changes in SOFA score and log-transformed biomarker concentrations between baseline (0 h) and 24 hours were analysed using linear regression models.

To explore the predictive value of biomarker concentrations and their kinetics for in-hospital mortality, joint models for longitudinal and time-to-event data were used. These models combined a linear mixed-effects model for each biomarker with a relative risk model for survival, including age and maximum SOFA score as potential confounders. The JMbayes2 package was used for joint modeling [18].

A Bayesian approach was used to fit the joint models, with posterior distributions approximated using three MCMC chains of 300,000 iterations each. The first 60,000 iterations were discarded as burn-in, and every 100th iteration was retained to reduce autocorrelation. Trace plots of the simulated values indicated good overlap between chains, suggesting stabilization. Convergence to the posterior distribution was further assessed using the potential scale reduction factor ($\hat{R}$), with all values close to 1, indicating convergence.

R version 4.4.0 was used for all analyses [19].

RESULTS

Between September 2022 and June 2024, 214 patients were screened and accepted as participants. Of these, 196 satisfied the inclusion/exclusion criteria and 173 had data available for analysis (at least one measure of each biomarker/inflammatory mediator), as well as having their survival recorded at discharge (see Fig. 1). 137 patients (79%) developed sepsis within 24 hours of arriving at the ED and the rest were categorized as infections without sepsis n=36 (21%).

Baseline characteristics and comorbidities are summarised in Table 1. Patients who developed sepsis were older and had similar comorbidities to those who did not. The sites of infection were mostly respiratory and urinary. The most commonly isolated pathogens (bacteremic or non-bacteremic) in non-septic patients were *E. coli* and *K. pneumoniae*,

whereas in septic patients, the most commonly isolated pathogens were Enterobacteriaceae and *S. pneumoniae* (eTable 1). The outcomes for patients with sepsis were worse, requiring more ICU admissions and significantly lower survival rates with an in-hospital mortality of 29 (21%) in the group of sepsis compared with none in the non-septic group (see eFig 1).

A swimmer-plot summarising the description of samples obtained and follow-up is provided in eFig 2. Multiplex bead analyses for inflammatory mediators were performed in duplicate, and the quality and reading description are provided in eTable 2. The trajectories of each biomarker are shown in eFig3.

Dynamics of biomarkers according to sepsis diagnosis

Linear mixed models were used to evaluate the associations between biomarkers over time and sepsis diagnosis. Those biomarkers for which more than 50% of the measures were below the limit of quantification were excluded, as their trend was flat (IFNG, IL1B, IL7, IL17A, CCL7, TNF) (eTable 3). In all patients with suspected infection included, IL10 (β estimate CI95% -0.016, -0.028 to -0.004), IL1RN (β estimate CI95% -0.014, -0.024 to -0.004) and IL6 (β estimate CI95% -0.012, -0.024 to 0.00) showed a significant decrease over time (per hour). Sepsis diagnosis was associated with higher values of IL1RN (β estimate, 95% CI: 0.378, 0.153 to 0.603) and TNFRSF1A (β estimate, 95% CI: 0.40, 0.21 to 0.58). Only IL-6 showed a significant interaction between a sepsis diagnosis and time (β estimate CI95% -0.14, -0.028 to 0.00) (Fig. 2). This means that patients with sepsis experienced a steeper decrease in IL-6 levels over time (per hour). The results are summarised in eTable 3 and eFig4.

Association of the severity of organ dysfunction on biomarkers levels

IL6 (β CI95% 0.048, 0.009 to 0.087), IL10 (β CI95% 0.048, 0.021 to 0.075), IL1RN (β CI95% 0.044, 0.017 to 0.071), CCL2(β CI95% 0.046, 0.021 to 0.071), TNFRSF1A (β CI95% 0.050, 0.030 to 0.070) and PCT (β CI95% 2.63 1.32 to 3.93) showed a significant association with organ dysfunction, where higher biomarker concentrations coincide with higher organ

dysfunction. There was also a significant association between the time in hours spent in the hospital and the levels of the same biomarkers, except for PCT (eTable 3, eFig 5). Only the interaction between time and SOFA score was significant for IL6, showing that IL6 decreased with higher SOFA at 24 hours (β CI95% -0.003, -0.005 to -0.001) (Fig 3), rather than increasing as in the early stages. The results are summarised in eTable 3 and eFig. 5. A linear regression model between IL-6 delta and SOFA score delta (24-hour results minus baseline results) was performed to corroborate whether patients with a higher fall in IL6 levels have a higher fall in SOFA score. No correlation was observed between the deltas (Fig 3).

Survival prediction

Associations between the concentrations of inflammatory biomarkers and in-hospital mortality were evaluated in joint model analyses. IL8, TNFRSF1A, and PCT were associated with the hazard of death (Table 2).

Results of joint modelling, evaluating biomarkers (IL10, IL1RN, IL6, CCL2, STREM-1) that were not associated with survival probability are shown in etable4.

The joint models were tested for convergence, discrimination and calibration. The discriminatory capacity was evaluated using receiver operating characteristic (ROC) curves, which were constructed to assess the ability to predict the event at 1024 hours based on biomarker measured at 24 hours. The area under the curve for the ROC curves for each model was as follows: 0.56 for evaluating the value of log TNFRSF1A, 0.63 for evaluating the value of log IL8, and 0.60 for evaluating PCT. The Brier scores were 0.13, 0.12 and 0.16, respectively. The ROC curves and calibration plots are shown in eFigs 6-7.

DISCUSSION

In this study, we analysed the dynamics of inflammatory markers in patients suspected of having an infection within the first 24 hours of receiving ED care. The study was developed with the aim of understanding how several factors inherent to sepsis, severity of organ

dysfunction and/or time, are associated with changes in the measures of inflammatory mediators and their implications for prognosis. Our main finding comprises: IL10, IL1RN, and IL6 decreased in the first 24 hours in all included patients, while IL1RN increased with the diagnosis of sepsis. Only IL6 showed a significant change in trend when patients had a sepsis diagnosis; IL6 had a fast step decrease in those patients (Fig 2). For the association between the SOFA score and the inflammatory mediators over time, IL10, IL1RN, CCL2, TNFRSF1A, and PCT increased along with the SOFA score. Time measured in hours was associated with decreased values, with the exception of PCT, meaning that the biomarker value may be associated with a lower SOFA score on arrival or a higher SOFA score after 24 hours. In the case of IL6, the interaction between time and SOFA was significant, confirming the findings of a sepsis diagnosis, meaning that the association between SOFA and IL6 was reversed after 24 hours (Fig. 3). The ability to predict is significantly impacted by this issue. It is crucial to recognise that the harm caused by inflammation appears to be associated with the initial hours of the inflammatory response. Regarding outcome prediction, time-dependent concentrations of TNFRSF1A, IL8 and PCT during the first 24 hours were associated with the risk of in-hospital mortality and could be useful for prognosis, but with low discriminatory capacity.

The importance of our findings lies in the fact that, despite advances in the pathophysiology of sepsis, few clinical studies have focused on the kinetics of inflammatory mediators during the earliest hours of hospital care. Longitudinal analysis of data enables us to understand the behaviour of inflammatory responses and to characterise patients dynamically. Van Deuren described the kinetics of TNF, TNFRSF1A, IL1B, and IL1RN. He based his observations mainly on those in critical care patients. While IL1B and TNF showed a decrease within the first 8 hours, TNFRSF1A and IL1RN exhibited greater variability, demonstrating a smaller decrease within the first 8 hours [10]. In another study describing the evolution of meningococcal disease, TNF and IL1B were below the limit of quantification, as in our study, and although IL6 levels increased, ex vivo production was suppressed [20]. A study describing the kinetics of IL6 after septic shock onset found that the IL6 peak occurred near the shock onset and decreased within 24

hours [21]. The kinetics of IL6 showed that a rapid decline within 24–48 hours was associated with successful antimicrobial therapy[22]. In our study, patients with sepsis or worst SOFA score had a significantly higher probability of decreasing IL6 levels during the first 24hs. PCT is one of the widely studied biomarkers in sepsis and has been shown to be associated with prognosis [23–26] and the capacity to guide antibiotic stewardship [27–29]. PCT may increase in the first 24 hs[30], followed by a decrease in the next days. Patients who didn´t achieve a decrease in the levels of more than 80% have a lower survival probability [30]. In concordance, we observed that the time-dependent values of PCT were associated with the probability of survival.

Kellum et al[31], describing the kinetics of IL10, TNF and IL6 in a cohort of patients with pneumonia, during the first days of admission. They observed, as in our study, that there is an overlap in biomarker levels between those who developed or did not develop sepsis (former severe sepsis) (Fig 2 and eFig3), and when categorising the continuous variables, mortality was higher in those with high levels of inflammatory mediators. We observed that patients with a confirmed infection and a clear systemic response (NEWS2 >3), but not sepsis, may exhibit a similar dysfunctional immune response in terms of biomarkers as those with sepsis. This emphasises the need for a clearer definition of dysregulated responses and the concept of pre-sepsis[32]. Surprisingly, the results obtained for IL8 and TNFRSF1A predict survival with an HR below one, indicating that those with higher values in repeated measures show a better prognosis. This is opposed to what has been observed in other studies with single measures and should be confirmed.

In recent years, several endotypes or subphenotypes have been identified in sepsis and other critical illnesses, depending on the patient's inflammatory status or genomic expression [33–35]. Nevertheless, inflammation otherwise to some chronic conditions is not static in sepsis, changing faster even in a short time. While some retrospective analyses of clinical trial data have demonstrated the potential for improved management based on different subphenotypes or profiles (17, 18), the heterogeneity of patients and the observation that subphenotypes can change within the first few hours or days underscore

the necessity for a more comprehensive understanding of the temporal evolution of inflammatory mediators [36–39].

Our study has strengths and limitations that should be acknowledged. The main strength lies in our protocol, which includes multiple samples within the first 24 hours, a sepsis diagnosis verified by blinded researchers, and statistical methods incorporating Linear mixed models for repeated measures [40] and joint models for longitudinal and time-to-event data, where we account for informative missingness of biomarker measures due to death. These methods are the most appropriate approach for assessing the impact of potential biomarkers and for dynamically updating patient prognosis [41]. We chose three times, considering the baseline, the response to early bundles and the response to 24hs. In terms of limitations, firstly, as this is a single-centre study, the results could be influenced by the population studied. Secondly, the analysis of several inflammatory mediator measures was limited to measures above the limit of quantification. Additionally, we must consider the short time between the first two measures, which means that the sensitivity of the test could influence differences in levels. Also, not all patients are observed over the entire 24h period. Finally, the patients included in this study may have had less severe disease than those in other studies. Quarterly, we assumed time zero to be at the point of ER arrival, but this is an arbitrary decision based on the most effective way to analyse our data.

In conclusion, our comprehensive study has improved our understanding of how sepsis and organ dysfunction affect inflammatory mediators/markers during the first 24 hours after hospital admission for infection. We found that inflammation is dynamic and that the development of sepsis/organ dysfunction over time may affect inflammatory mediators and/or biomarkers within the first 24 hours of arrival at the ED in patients at risk of sepsis. IL-6 exhibits different kinetics depending on whether or not the patient develops sepsis within the first 24 hours. IL6, IL10, IL-1RN, CCL2, TNFRSF1A and PCT values were associated with the SOFA score, with different values observed at each time point (except for PCT). Finally, we demonstrated the predictive capacity of longitudinal data for survival

probability. TNFRSF1A, IL8, and PCT were associated with survival and could be useful in developing prognostic tools; however, their discriminatory capacity was low.

Abbreviations

AUCROC (AUC) – Area Under the ROC Curve

CCL2 – C-C motif chemokine ligand 2

CCL7 – C-C motif chemokine ligand 7

CI95% – 95% Confidence Interval

ED – Emergency Department

ELISA – Enzyme-Linked Immunosorbent Assay

HR – Hazard Ratio

ICU – Intensive Care Unit

IFNG – Interferon gamma

IL1B – Interleukin 1 beta

IL1RN – Interleukin 1 receptor antagonist

IL6 – Interleukin 6

IL7 – Interleukin 7

IL8 – Interleukin 8

IL10 – Interleukin 10

IL17A – Interleukin 17A

MCMC – Markov Chain Monte Carlo

NEWS – National Early Warning Score

PCT – Procalcitonin

qSOFA – quick Sequential Organ Failure Assessment

$\hat{R}$ (R-hat) – Potential Scale Reduction Factor

ROC – Receiver Operating Characteristic (curve)

SOFA – Sequential Organ Failure Assessment

STREM-1 – Soluble Triggering Receptor Expressed on Myeloid cells-1

STROBE – Strengthening the Reporting of Observational Studies in Epidemiology

TNF – Tumor Necrosis Factor

TNFRSF1A – Tumor Necrosis Factor Receptor Superfamily Member 1A

Ethical statement: The institution's Ethical Review Board approved the study (Comité de Ética de Investigación con medicamentos del Parc Taulí 2022/3004), which was conducted in accordance with the ethical standards set out in the 1964 Declaration of Helsinki and its subsequent amendments. Written informed consent was obtained from all patients or their legally authorised surrogates.

Data Availability: The datasets used and/or analysed during the current study are available from CORA.Repositori de Dades de Recerca, https://doi.org/10.34810/data3142.

Conflict of interest: The authors have no conflict of interest.

Funding: This study was supported by the Ministry of Science: CPP2021-008394. CIBERES, and Research and Innovation Institute Parc Tauli (I3PT). AC acknowledges receiving financial support from Instituto de Salud Carlos III CD21/00087, MV23/00097 and PI 23:00106. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and in the decision to submit the manuscript for publication.

Authors' contribution: AC & AA Study supervision. All authors reviewed and approved the manuscript for submission. **Authors' contributions:** BC, VM, MCR, ED, EG, LB, AA and AC participated in protocol development, study design, study management, statistical analysis, and data interpretation. AF, LK, RvA, LB and AC participated in statistical analysis. BC, ACa; EN; PS; CG; JT; GG; and MLM participated in data collection. VM, MCR, AAB, and ECD participated in sample analyses. All authors read and approved the final manuscript.

Acknowledgments: We are indebted to all our medical and nursing colleagues for their assistance and cooperation in this study.

Figure 1. Flowchart

Study recruitment overview. Adjudication of sepsis was performed by at least two physicians based on the Sepsis-3 definition[2].

Figure 2 Linear mixed-effect plot for IL-6, and time according to sepsis diagnosis.

Trajectories of plasma concentration IL6 during the first 24 hs by groups assigned whether or not the patients developed sepsis. Lines represent the fitted linear mixed model. Each point represents the concentration of IL-6 for each subject.

Fig 3. Linear mixed-effect plot for IL-6, and SOFA score according to time sampling and relation between changes of IL-6 and SOFA score at 24 hs.

Above: Linear mixed model estimations of plasma concentration of IL6 according to SOFA score and time sampling. Lines represent the fitted linear mixed model. Each point represents the concentration of IL-6 for each subject. Below: Changes in SOFA score between 0 and 24 hours associated with changes in log-transformed IL-6 levels over the same period, with the regression line and corresponding slope, correlation

coefficient, and coefficient of determination indicating the strength and direction of this relationship. β = regression coefficient. r= Pearson correlation coefficient. R^2= coefficient of determination.

p=p-value

Table 1. Demographic and clinical characteristics at time 0 of patients by sepsis status.

Variable	Non-Sepsis (n=36)	Sepsis (n=137)	p-value
Age, years (median [IQR])	69.5 [55.75, 79]	78 [67.00, 85]	0.005
BMI, kg/m^2 (median [IQR])	26.6 [24.2, 31.3]	25.75 [22.52, 29.62]	0.40
Sex male, n(%)	29 (80.6%)	87 (63.5%)	0.08
Charlson Comorbidity Index (median [IQR])	5 [3, 7]	5 [4, 7]	NS
Coronary disease, n(%)	4 (11.1%)	18 (13.1%)	1.0
Chronic Heart Failure, n(%)	4 (11.1%)	28 (20.4%)	0.29
Peripheral Vascular Disease, n(%)	5 (13.9%)	19 (13.9%)	1.0
Cerebrovascular Disease, n(%)	5 (13.9%)	29 (21.2%)	0.45
Chronic Pulmonary Disease, n(%)	13 (36.1%)	36 (26.3%)	0.33
Dementia, n(%)	6 (16.7%)	34 (24.8%)	0.41
Liver Disease, n(%)	4 (11.1%)	8 (5.8%)	0.27
Diabetes mellitus, n(%)	8 (22.2%)	39 (28.5%)	0.58
Chronic Kidney Disease, n(%)	10 (27.8%)	29 (21.2%)	0.53

Site of infection
   Respiratory
   Urinary
   Abdominal (non-surgical)
   Other
	
	21(60%)
	8(23%)
	1(3%)
	5(13%)
		
		55(40%)
		38(28%)
		25(18%)
		17(13%)
			0.11

Days since the onset of symptoms, Median [Q1, Q3]	2 [0, 3]	2 [0, 4]	0.99
Systolic Blood Pressure mmhg (median [IQR])	114.5 [94.75, 130.75]	97 [85, 114]	0.007
Diastolic Blood Pressure mmHg (median [IQR])	64.5 [57.25, 82.25]	57 [49, 68]	0.003
Respiratory Rate per min (median [IQR])	34 [31, 36.50]	23.50 [20, 30]	0.021
Heart Rate per min (median [IQR])	110 [86.5, 122.25]	98 [78, 115.50]	0.07
SOFA Score (median [IQR])	1 [1, 1]	3 [2, 5]	<0.0001
APACHE Score (median [IQR])	9 [6.75, 11]	12 [9.50, 16]	0.0005
NEWS2 Score (median [IQR])	5 [4, 6]	6 [4, 8]	0.06
qSOFA Score (median [IQR])	1 [0, 1]	1 [0.75, 1]	0.0007
SpO2/FiO2 Ratio (median [IQR])	442.86 [383.33, 457.14]	419.05 [339.29, 452.38]	0.21
PaO2/FiO2 Ratio (median [IQR])	333.33 [264.52, 380.95]	277.38 [196.62, 380.95]	0.32
Leukocytes 10^9/L(median [IQR])	12.34 [9.55, 15.85]	12.36 [7.52, 18.34]	0.79
Lymphocytes % (median [IQR])	8.00 [4, 12.5]	6.00 [4, 10.25]	0.79
Neutrophils % (median [IQR])	85 [70.5, 89.5]	87 [79.75, 91]	0.21
Absolute Neutrophils/ Lymphocytes ratio	10.6 [7.25, 20.4]	14.1 [7.17, 19.6]	0.616

CRP mg/dL(median [IQR])	6.28 [4.03, 16.12]	11.69 [3.31, 25.84]	0.11
Lactate mmol/L (median [IQR])	1.68 [1.31, 2.22]	2.51 [1.49, 3.54]	0.005
pH (median [IQR])	7.38 [7.34, 7.43]	7.38 [7.33, 7.43]	0.81
paO2 mmHg (median [IQR])	80.00 [75.00, 82.00]	80.00 [64.38, 87.92]	0.83
paCO2 mmHg (median [IQR])	41.00 [37.28, 44.65]	35.20 [32.00, 43.20]	0.0445
Bicarbonate meq/L (median [IQR])	23.20 [22.50, 26.10]	21.90 [19.40, 24.58]	0.0326
Creatinine mg/dL (median [IQR])	0.94 [0.82, 1.11]	1.24 [0.95, 1.97]	0.0015
Glucose mg/dL (median [IQR])	125 [106.50, 145.25]	143 [118, 185.50]	0.051
Bilirubin mg/dL (median [IQR])	0.6 [0.4, 0.75]	0.8 [0.5, 1.35]	0.0028
Bacteremic disease	7 (19.4%)	35 (25.5%)	0.0405
Adequate Antibiotics, n(%)	29 (80.6%)	118 (86.1%)	1.0
ICU admission, n(%)	1 (2.8%)	29 (21.2%)	0.019
Septic Shock, n(%)	0 (0.0%)	19 (13.9%)	0.014
Mortality, n(%)	0 (0.0%)	29 (21.2%)	0.005

APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; CRP, C-reactive protein; FiO_2, fraction of inspired oxygen; ICU, Intensive Care Unit; IQR, interquartile range; MV, mechanical ventilation; NEWS, national early warning score; $PaCO_2$, arterial partial pressure of carbon dioxide; PaO_2, partial pressure of arterial oxygen; qSOFA: quick sequential organ failure assessment score; SpO2: peripheral oxygen saturation SOFA: sequential organ failure assessment score.

Table 2. Results of joint modeling for longitudinal measures and time to event.

Parameter of interest	Parameter	Hazard Ratio	Lower 95% Credible Interval	Upper 95% Credible Interval	P_{Bayes}
Joint modelling evaluating IL8	Age	1.068	0.955	1.182	0.202
	Highest SOFA score	1.415	1.025	1.856	0.042
	IL8	0.655	0.582	0.728	0.000
Joint modelling evaluating TNFRSF1A	Age	1.066	0.948	1.181	0.216
	Highest SOFA score	1.444	1.042	1.892	0.035
	TNFRSF1A	0.505	0.419	0.682	0.010
Joint modelling evaluating PCT	Age	1.085	1.032	1.145	0.002
	Highest SOFA score	1.402	1.174	1.673	0.001
	PCT	1.004	1.001	1.008	0.000

Results are obtained by joint models analyses, corrected for age, and the highest SOFA at the day of sampling. Joint model analysis was used to evaluate the longitudinal changes in plasma biomarker concentrations and the association between changes in biomarker concentration and outcomes. Joint modelling analyses two types of data: repeated measurements over time and time-to-event data (survival data). P_{Bayes} indicates the posterior probability that the parameter differs from zero, as estimated from the joint Bayesian models. Credible intervals represent the ranges containing the true parameter value with 95% posterior probability.

References:

1. Gray, A. P. *et al.* Global, regional, and national sepsis incidence and mortality, 1990–2021: a systematic analysis. *The Lancet Global Health* **0**, (2025).

2. Singer, M. *et al.* The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* **315**, 801–810 (2016).

3. Evans, L. *et al.* Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. *Critical Care Medicine* **49**, e1063 (2021).

4. Angus, D. C. & van der Poll, T. Severe Sepsis and Septic Shock. *New England Journal of Medicine* **369**, 840–851 (2013).

5. Walton, A. H. *et al.* Determining potential immunomodulatory drug efficacy in sepsis using ELISpot. *Sci Rep* **15**, 13464 (2025).

6. Rello, J. *et al.* Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. *Clin Microbiol Infect* **24**, 1264–1272 (2018).

7. Cajander, S. *et al.* Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine. *Lancet Respir Med* **12**, 305–322 (2024).

8. Shankar-Hari, M. *et al.* Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies. *Lancet Respir Med* **12**, 323–336 (2024).

9. Meyer, N. J. & Prescott, H. C. Sepsis and Septic Shock. *New England Journal of Medicine* **391**, 2133–2146 (2024).

10. van Deuren, M. Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections. *Eur J Clin Microbiol Infect Dis* **13 Suppl 1**, S12-16 (1994).

11. Harhay, M. O. *et al.* Assessing the Course of Organ Dysfunction Using Joint Longitudinal and Time-to-Event Modeling in the Vasopressin and Septic Shock Trial. *Crit Care Explor* **2**, e0104 (2020).

12. National Early Warning Score (NEWS) 2. https://www.rcplondon.ac.uk/improving-care/resources/national-early-warning-score-news-2/.

13. Vincent, J. L. *et al.* The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med* **22**, 707–710 (1996).

14. Yébenes, J. C. *et al.* Código Sepsis Interhospitalario en Catalunya: modelo organizativo territorial para la atención inicial al paciente con sepsis. *Med Intensiva* **44**, 36–45 (2020).

15. Ceccato, A. *et al.* Regional sepsis care in Catalonia: comparative insights from a secondary analysis of the European Sepsis Care Survey. *Crit Care* **29**, 367 (2025).

16. von Elm, E. *et al.* The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* **147**, 573–577 (2007).

17. version), J. P. (S *et al.* nlme: Linear and Nonlinear Mixed Effects Models. (2025).

18. Rizopoulos D, Papageorgiou G, Miranda Afonso P, D. JMbayes2. https://drizopoulos.github.io/JMbayes2/.

19. R Core Team. R: A language and environment for statistical computing [Internet]. R Foundation for Statistical Computing; 2022.

20. van Deuren, M. *et al.* Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. *J Infect Dis* **169**, 157–161 (1994).

21. Calandra, T., Gerain, J., Heumann, D., Baumgartner, J. D. & Glauser, M. P. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. *Am J Med* **91**, 23–29 (1991).

22. Klag, T., Cantara, G., Sechtem, U. & Athanasiadis, A. Interleukin-6 Kinetics can be Useful for Early Treatment Monitoring of Severe Bacterial Sepsis and Septic Shock. *Infect Dis Rep* **8**, 6213 (2016).

23. Jensen, J. U. *et al.* Procalcitonin increase in early identification of critically ill patients at high risk of mortality. *Crit Care Med* **34**, 2596–2602 (2006).

24. Mat Nor, M. B. & Md Ralib, A. Procalcitonin Clearance for Early Prediction of Survival in Critically Ill Patients with Severe Sepsis. *Crit Care Res Pract* **2014**, 819034 (2014).

25. Tong-Minh, K. *et al.* Soluble urokinase plasminogen activator receptor and procalcitonin for risk stratification in patients with a suspected infection in the emergency department: a prospective cohort study. *European Journal of Emergency Medicine* **30**, 324 (2023).

26. Viallon, A. *et al.* Can emergency physicians identify a high mortality subgroup of patients with sepsis: role of procalcitonin. *Eur J Emerg Med* **15**, 26–33 (2008).

27. Schuetz, P. *et al.* Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. *Lancet Infect Dis* **18**, 95–107 (2018).

28. Schuetz, P. *et al.* Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev* **10**, CD007498 (2017).

29. Dark, P. *et al.* Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial. *JAMA* **333**, 682–693 (2025).

30. Schuetz, P. *et al.* Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study. *Crit Care Med* **45**, 781–789 (2017).

31. Kellum, J. A. *et al.* Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. *Arch. Intern. Med.* **167**, 1655–1663 (2007).

32. Gerard, R. *et al.* Is 'pre-sepsis' the new sepsis? A narrative review. *PLoS Pathog* **21**, e1013372 (2025).

33. Calfee, C. S. *et al.* ARDS Subphenotypes and Differential Response to Simvastatin: Secondary Analysis of a Randomized Controlled Trial. *Lancet Respir Med* **6**, 691–698 (2018).

34. Meyer, N. J. *et al.* Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*. *Critical Care Medicine* **46**, 21 (2018).

35. Antcliffe, D. B. *et al.* Patient stratification using plasma cytokines and their regulators in sepsis: relationship to outcomes, treatment effect and leucocyte transcriptomic subphenotypes. *Thorax* **79**, 515–523 (2024).

36. Ceccato, A. *et al.* Clustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort. *Critical Care* **28**, 91 (2024).

37. Ceccato, A., Peñuelas, O. & Artigas, A. Dynamics of Subphenotypes in Critical Illness: When the Tick-Tock of the Clock Counts. *Am J Respir Crit Care Med* **211**, 305–307 (2025).

38. van Amstel, R. B. E. *et al.* Temporal Transitions of the Hyperinflammatory and Hypoinflammatory Phenotypes in Critical Illness. *Am J Respir Crit Care Med* **211**, 347–356 (2025).

39. Slim, M. A. *et al.* Clinical Subtype Trajectories in Sepsis Patients Admitted to the ICU: A Secondary Analysis of an Observational Study. *Critical Care Explorations* **6**, e1176 (2024).

40. Detry, M. A. & Ma, Y. Analyzing Repeated Measurements Using Mixed Models. *JAMA* **315**, 407–408 (2016).

41. Rué, M. *et al.* Bayesian joint modeling of bivariate longitudinal and competing risks data: An application to study patient-ventilator asynchronies in critical care patients. *Biom J* **59**, 1184–1203 (2017).